FIG. 1



MIA PaCa-2
% Inhibition
100
80
60
40
20
0
-20
10
3
1
0.3
Concentration (nM)
10
3
1
Olaparib (μM)
Compound 24 alone (nM)
Compound 24 + Olparib 1 μM
Compound 24 + Olparib 3 μM
Compound 24 + Olparib 10 μM

FIG. 2



MDA-MB-231
% inhibition
100
80
60
40
20
0
100
10
1
0.1
0.01
Concentration (nM)
10
1
0.1
0.01
BMN-673 (nM)
Compound 24 alone
Compound 24 + BMN 0.01 nM
Compound 24 + BMN 0.1 nM
Compound 24 + BMN 1 nM
Compound 24 + BMN 10 nM

FIG. 3



MIA PaCa-2
% Inhibition
100
80
60
40
20
0
10
3
1
0.3
Concentration (nM)
1
0.3
0.1
Afatinib (µM)
Compound 24 alone (nM)
Compound 24 + Afatinib 0.1 µM
Compound 24 + Afatinib 0.3 µM
Compound 24 + Afatinib 1 µM

FIG. 4



MIA PaCa-2
% Inhibition
100
80
60
40
20
0
1
0.1
0.01
Concentration (nM)
3
5
10
BI-3406 (μM)
Compound 24 alone
Compound 24 + BI-3406 3 μM
Compound 24 + BI-3406 5 μM
Compound 24 + BI-3406 10 μM

FIG. 5



MDA-MB-231
% Inhibition
100
80
60
40
20
0
1000
100
10
1
0.1
0.01
0.001
0.0001
Concentration (nM)
0.03
0.1
0.3
1
Afatinib (uM)
= Compound 24 alone (nM)
Compound 24 + Afatinib 0.03 uM
Compound 24 + Afatinib 0.1 uM
Compound 24 + Afatinib 0.3 uM
Compound 24 + Afatinib 1 uM

FIG. 6



MDA-MB-231
% Inhibition
100
80
60
40
20
0
-20
10000
1000
100
10
1
0.1
0.01
0.001
Concentration (nM)
1
0.1
0.03
0.01
0.001
Abemaciclib (μM)
Compound 24 alone (nM)
Compound 24 + Abemaciclib 0.001 μM
Compound 24 + Abemaciclib 0.01 μM
Compound 24 + Abemaciclib 0.03 μM
Compound 24 + Abemaciclib 0.1 μM
Compound 24 + Abemaciclib 1 μM

FIG. 7





MIA PaCa-2
% Inhibition
100.00
80.00
60.00
40.00
20.00
0.00
-20.00
1000
100
10
3
1
0.1
0.01
Concentration (nM)
0.03
0.1
0.3
1
Compound 24 (nM)
AMG-510 alone
AMG-510 + 0.03 nM Compound 24
AMG-510 + 0.1 nM Compound 24
AMG-510 + 0.3 nM Compound 24
AMG-510 + 1 nM Compound 24

FIG. 8




Two-way ANOVA followed by Bonferroni's *post-hoc* test* (p *<0.05; **<0.01; ***<0.001)

FIG. 9



Two-way ANOVA followed by Bonferroni's post-hoc test* (p *<0.05; **<0.01; ***<0.001)

FIG. 10



Two-way ANOVA followed by Bonferroni's post-hoc test* (p *<0.05; **<0.01; ***<0.001)